Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBPβ-deficient mice

Journal of Experimental Medicine

Volumn 184, Issue 4, 1996, Pages 1561-1566

  Screpanti, Isabella ^a   Musiani, Piero ^b   Bellavia, Diana ^c   Cappelletti, Manuela ^f   Aiello, Francesca B ^b   Maroder, Marella ^a,d   Frati, Luigi ^a,e   Modesti, Andrea ^b   Gulino, Alberto ^c   Poli, Valeria ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e IRCCS NEUROMED   (Italy)

^f IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TRANS ACTING FACTOR; TRANS ACTING FACTOR C EBP BETA; UNCLASSIFIED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANIMAL CELL; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; GERMINAL CENTER; LYMPH NODE; MOUSE; NONHUMAN; PLASMACYTOSIS; PRIORITY JOURNAL; SPLEEN CELL; THYMOCYTE;

ANIMALS; B-LYMPHOCYTES; CCAAT-ENHANCER-BINDING PROTEINS; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GIANT LYMPH NODE HYPERPLASIA; INTERLEUKIN-6; LYMPH NODES; MICE; MICE, MUTANT STRAINS; NUCLEAR PROTEINS; PHENOTYPE; PLASMA CELLS; SPLEEN; THYMUS GLAND;

EID: 10244246599     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.184.4.1561     Document Type: Article

References (16)

1. Peterson, B.A., and G. Frizzera. 1993. Multicentric Castleman's disease. Semin. Oncol. 20:636-647.
2. Yoshizaki, K., T. Matsuda, N. Nishimoto, T. Kuritani, L. Taeho, K. Aozasa, T. Nakahata, K. Kawai, H. Tagoh, T. Komori et al. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 74:1360-1367.
3. Brandt, S.J., D.M. Bodine, C.E. Dunbar, and A.W. Nienhuis. 1990. Disregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86:592-599.
4. Beck, J.T., S-M. Hsu, J. Wijdeness, R. Bataille, B. Klein, D. Vesole, K. Hayden, S. Jagannath, and B. Barlogie. 1994. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. New Engl. J. Med. 330:602-605.
5. Hirano, T., S. Akira, T. Taga, and T. Kishimoto. 1990. Biological and clinical aspects of interleukin 6. Immunol. Today. 11:443-449.
6. Kawano, M.M., K. Mihara, N. Huang, T. Tsujimoto, and A. Kuramoto. 1995. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood. 85:487-494.
7. Akira, S., H. Issihiki, T. Sugita, O. Tanabe, S. Kinoshita, Y. Nishio, T. Nakajima, T. Hirano, and T. Kishimoto. 1990. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO (Eur. Mol. Biol. Organ.) J. 9:1897-1906.
8. Poli, V., F.P. Mancini, and R. Cortese. 1990. IL6-DBP, a nuclear protein involved in interleukin 6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell. 63:643-653.
9. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Kohler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (Lond.). 368:339-342.
10. Poli, V., R. Balena, E. Fattori, A. Markatos, M. Yamamoto, H. Tanaka, G. Ciliberto, G.A. Rodan, and F. Costantini. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO (Eur. Mol. Biol. Organ.) J. 13:1189-1196.
11. Screpanti, I., L. Romani, P. Musiani, A. Modesti, E. Fattori, D. Lazzaro, C. Sellitto, S. Scarpa, D. Bellavia, G. Lattanzio et al. 1995. Lymphoprolipherative disorder and imbalanced T-helper response in C/EBPβ-deficient mice. EMBO (Eur. Mol. Biol. Organ.) J. 14:1932-1941.
12. Tanaka, T., S. Akira, K. Yoshida, M. Umemoto, Y. Yoneda, N. Shirafuji, H. Fujiwara, S. Suematsu, N. Yoshida and T. Kishimoto. 1995. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell. 80:353-361.
13. Zhang, X.G., B. Klein, and R. Bataille. 1989. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 74:11-13.
14. Asimakopoulos, F.A., N.J. White, E. Nacheva, and A.R. Green. 1994. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood. 84:3086-3094.
15. Roulston, D., R. Espinosa III, M. Stoffel, G.I. Bell, and M.M. Le Beau. 1993. Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood. 82:3424-3429.
16. White, N.J., E. Nacheva, F.A. Asimakopoulos, D. Bloxham, B. Paul, and A.R. Green. 1994. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood. 83:2809-2816.